CEBPA and acute myeloid leukemia: Wang et al [36] reported high mutation rates (>10%) in CEBPA, NPM1, DNMT3A, FLT3-ITD, NRAS, IDH2 and WT1. Kihara et al [37] reported high mutation rates of FLT3, NPM1, CEBPA, DNMT3A and KIT mutations in Japanese patients with AML.